Mustang Bio Announces Presentation of MB-102 (CD123 CAR) Safety and Efficacy Data at AACR

Mustang Bio (NASDAQ:MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell technology and gene therapies for rare diseases, today announced that additional safety and efficacy Phase 1 data evaluating MB-102 (CD123 CAR) in relapsed or refractory acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) have been selected for an oral presentation at the AACR Special Conference on Tumor Immunology and Immunotherapy. The presentation will take place on November 30, 2018, in Miami Beach, Florida.

As quoted in the press release:

Martina Sersch, M.D., Ph.D., Chief Medical Officer of Mustang, said, “We are excited about the additional data demonstrating MB-102’s (CD123 CAR T) potential to treat patients with AML and BPDCN. Initial safety and tolerability data as well as preliminary data on efficacy are very promising in a population with high unmet medical need. Based on the Phase 1 data, we expect to submit an IND filing for MB-102 and look forward to initiating a multicenter Phase 1/2 clinical trial in 2019 in patients with AML, BPDCN and high-risk myelodysplastic syndrome.”

Lihua Elizabeth Budde, M.D., Ph.D., assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope and principal investigator for the Phase 1 trial, said, “There is increased expression of CD123 on AML blasts, leukemic stem cells and BPDCN cells compared to normal hematopoietic stem cells, and it is therefore a promising target for cellular immunotherapy. We remain encouraged by interim data showing MB-102’s potential to treat BPDCN and AML and continue to evaluate MB-102’s clinical benefits in our ongoing Phase 1 clinical trial.”

Click here to read the full press release.